权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Breast Cancer Therapeutic Agents Based on Telomerase Misfunction

基于端粒酶功能障碍的乳腺癌治疗剂

基本信息

批准号：
8250839
负责人：
ELIZABETH H BLACKBURN
金额：
$ 17.94万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/8250839
关键词：
Address Amplifiers Antibodies Antineoplastic Agents Apoptosis Apoptotic Archives Biological Biological Assay Biological Markers Biopsy Specimen Breast Breast Cancer Cell Breast Cancer Model Cancer cell line Catalytic RNA Cell Death Cell Line Cells Characteristics Chest Wall Disorder Clinic Clinical Clinical Trials Data Development Drug Formulations ERBB2 gene Freezing Functional disorder Funding Genes Genomics Goals Growth Immunoliposome In Vitro Laboratories Laboratory Research Length Libraries Malignant Neoplasms Mammary Neoplasms Measures Methods Modeling Molecular Molecular Profiling Monitor Neoplasm Metastasis Paraffin Embedding Pathway interactions Patients Pattern Performance RNA RNA Interference Regulation Rodent Rodent Model Sampling Science Series Small Interfering RNA Staging Stem cells System Telomerase Telomerase RNA Component Telomere Maintenance Testing Therapeutic Therapeutic Agents Tissue Sample Toxic Actions Toxicology Translating Translations Validation Work Xenograft Model Xenograft procedure anticancer treatment base cancer cell cancer therapy clinical application drug sensitivity functional status high throughput screening in vitro testing in vivo killings malignant breast neoplasm manufacturing scale-up mouse model mutant nanoparticle neoplastic cell research clinical testing response seal stem telomere therapeutic development tumor vector

项目摘要

The goal of UCSF Breast Cancer SPORE Project #4 is to develop and assess the translational potential of agents we have developed that force telomerase interference in breast cancer. This Project focuses on exploitation for clinical use of a new strategy: to turn the action of active telomerase against the breast cancer cells. In this current funding cycle, we have successfully demonstrated that a low threshold of expression of mutant-template telomerase RNA (MT-hTer) genes in human breast cancer cells is sufficient for a potent killing and growth inhibitory effect on these cells. The telomeres that result from MT-hTer action are "toxic" to cells, inducing a robust apoptotic response. Additionally, during the previous SPORE funding period, new science arising from the Blackburn laboratory's research on telomerase also led to two] unanticipated discoveries: first, that simply decreasing the endogenous telomerase level by ribozyme or RNA targeting methods rapidly decreased cancer potential. Specifically, we found that lowering overall telomerase diminishes the metastatic potential of cancer cells in vivo, and rapidly inhibited the growth of breast and other cancer cells in vitro. Second, cell death induced by MT-hTer expression is dominant and does not require the p53 or pRb checkpoint pathways. Based on these findings, we then showed that combining the expression of MT-hTer with small interfering RNA directed against the endogenous WT-hTER of cancer cells synergistically increases the potency of the MT-hTer effects in killing cancer cells. The following Specific Aims, which have the goal of bringing this work to the clinic, are to: #1 Further test and characterize the previously developed immunoliposome ("ILS") constituted with Her2-targeting antibody¿developed in SPORE Project 3¿containing the MT-hTer/anti-hTER siRNA construct ("MT-Rx" agent). In order to monitor MT-Rx efficacy we will use relevant biomarkers of response to the agent, suitable for early stage clinica trials. #2 Identify telomere/telomerase-based biomarker patterns predictive of apoptotic response t anticancer treatments and to specific MT-Rx therapy. We will identify the subset(s) of breast cancers that wil be most responsive to existing therapies and to "MT-Rx" using (i) a panel of 60 breast cancer cell line grouped by genomic and expression profiling, telomere maintenance status and other clinically relevan characteristics and (ii) patient-derived primary breast cancer cells, including stem/progenitor cell lines; tha targets the most sensitive patient subpopulation, as identified. #3. Validate and optimize the assays fo biomarkers of telomerase and telomere status on tumor and biopsy specimens, with the goal of validating] these assays per CLIA regulations in a CLIA certified laboratory such that the results can be used clinically.) Toward translation of MT-Rx, we will finalize the product configuration, perform initial manufacturing seal up, and evaluate initial toxicology targeted systemic delivery of MT-Rx agent in rodent models.

UCSF乳腺癌孢子项目#4的目标是开发和评估的转化潜力